Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer

Molecular Cancer Research

Volumn 12, Issue 9, 2014, Pages 1195-1204

  Das, Shipra ^a   Krainer, Adrian R ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MICRORNA; ONCOPROTEIN; PROTEIN SRSF1; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; RNA; RNA BINDING PROTEIN; SERINE-ARGININE-RICH SPLICING PROTEINS;

AMINO ACID SEQUENCE; CANCER RESEARCH; CARCINOGENESIS; CHROMATIN; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HELA CELL LINE; HUMAN; NONSENSE MEDIATED MRNA DECAY; NUCLEAR EXPORT SIGNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTO ONCOGENE; REVIEW; RNA METABOLISM; RNA PROCESSING; RNA TRANSLATION; SIGNAL TRANSDUCTION; SUMOYLATION; BIOSYNTHESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY; RNA SPLICING;

CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RNA; RNA SPLICING; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 84907263928     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0131     Document Type: Review

References (97)

1. Long JC, Cáceres JF. The SR protein family of splicing factors: master regulators of gene expression. Biochem J 2009;417:15-27.
2. Manley JL, Krainer AR. A rational nomenclature for serine/argininerich protein splicing factors (SR proteins). Genes Dev 2010;24: 1073-4.
3. Cáceres JF, Screaton GR, Krainer AR. A specific subset of SR proteins shuttles continuously between the nucleus and the cytoplasm. Genes Dev 1998;12:55-66.
4. Cowper AE, Cáceres JF, Mayeda A, Screaton GR. Serine-arginine (SR) protein-like factors that antagonize authentic SR proteins and regulate alternative splicing. J Biol Chem 2001;276:48908-14.
5. Sapra AK, Ankö ML, Grishina I, Lorenz M, Pabis M, Poser I, et al. SR protein family members display diverse activities in the formation of nascent and mature mRNPs in vivo. Mol Cell 2009;24:179-90.
6. Liu HX, Zhang M, Krainer AR. Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins. Genes Dev 1998;12:1998-2012.
7. Blencowe BJ. Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci 2000;25: 106-10.
8. Jumaa H, Wei G, Nielsen PJ. Blastocyst formation is blocked in mouse embryos lacking the splicing factor SRp20. Curr Biol 1999;9:899-902.
9. Moroy T, Heyd F. The impact of alternative splicing in vivo: mouse models show the way. RNA 2007;13:1155-71.
10. Wang HY, Xu X, Ding JH, Bermingham JR, Fu XD. SC35 plays a role in T cell development and alternative splicing of CD45. Mol Cell 2011;7:331-42.
11. Xu X, Yang D, Ding JH, Wang W, Chu PH, Dalton ND, et al. ASF/SF2 regulated CaMKIIdelta alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle. Cell 2005;120: 59-72.
12. Zhong XY, Wang P, Han J, Rosenfeld MG, Fu XD. SRproteins in vertical integration of gene expression from transcription to RNA processing to translation. Mol Cell 2009;35:1-10.
13. Twyfelles L, Gueydan C, Kruys V. Shuttling SR proteins: more than splicing factors. FEBS J 2011;278:3246-55.
14. Li X, Manley JL. Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell 2005;122:365-78.
15. Li X, Wang J, Manley JL. Loss of splicing factor ASF/SF2 induces G2 cell cycle arrest and apoptosis, but inhibits internucleosomal DNA fragmentation. Genes Dev 2005;19:2705-14.
16. Corbo C, Orru S, Salvatore F. SRp20: an overview of its role in human diseases. Biochem Biophys Res Commun 2013;436:1-5.
17. Krainer AR, Conway GC, Kozak D. Purification and characterization of pre-mRNA splicing factor SF2 from HeLa cells. Genes Dev 1990; 4:1158-71.
18. Krainer AR, Conway GC, Kozak D. The essential pre-mRNA splicing factor SF2 influences 50 splice site selection by activating proximal sites. Cell 1990;62:35-42.
19. Ge H, Manley JL. A protein factor, ASF, controls cell-specific alternative splicing of SV40 early pre-mRNA in vitro. Cell 1990;62:25-34.
20. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007;14:185-93.
21. Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell 2005;20:881-90.
22. Anczuków O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, et al. The splicing-factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 2012;19:220-8.
23. Cáceres JF, Krainer AR. Functional analysis of pre-mRNA splicing factor SF2/ASF structural domains. EMBO J 1993;12:4715-26.
24. Zuo P, Manley JL. Functional domains of the human splicing factor ASF/SF2. EMBO J 1993;12:4727-37.
25. Cáceres JF, Misteli T, Screaton GR, Spector DL, Krainer AR. Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity. J Cell Biol 1997;138:225-38.
26. Mayeda A, Screaton GR, Chandler SD, Fu XD, Krainer AR. Substrate specificities of SR proteins in constitutive splicing are determined by their RNA recognition motifs and composite pre-mRNA exonic elements. Mol Cell Biol 1999;19:1853-63.
27. Cléry A, Sinha R, Anczuków O, Corrionero A, Moursy A, Daubner GM, et al. Isolated pseudo-RNA-recognition motifs of SR proteins can regulate splicing using a noncanonical mode of RNA recognition. Proc Natl Acad Sci U S A 2013;110:E2802-11.
28. Pandit S, Zhou Y, Shiue L, Coutinho-Mansfield G, Li H, Qiu J, et al. Genome-wide analysis reveals SR protein cooperation and competition in regulated splicing. Mol Cell 2013;50:223-35.
29. Sanford JR, Wang X, Mort M, Vanduyn N, Cooper DN, Mooney SD, et al. Splicing factor SRSF1 recognizes a functionally diverse landscape of RNA transcripts. Genome Res 2009;19:381-94.
30. Ray D, Kazan H, Chan T, Peña Castillo L, Chaudhry S, Talukder S, et al. Rapid and systematic analysis of the RNA recognition specificities of RNA-binding proteins. Nat Biotechnol 2009;27:667-70.
31. Wang J, Smith PJ, Krainer AR, Zhang MQ. Distribution of SR protein exonic splicing enhancer motifs in human protein-coding genes. Nucleic Acids Res 2005;33:5053-62.
32. Tacke R, Manley JL. The human splicing factors ASF/SF2 and SC35 possess distinct, functionally significant RNA binding specificities. EMBO J 1995;14:3540-51.
33. Zhu J, Krainer AR. Pre-mRNA splicing in the absence of an SR protein RS domain. Genes Dev 2000;14:3166-78.
34. Shaw SD, Chakrabarti S, Ghosh G, Krainer AR. Deletion of the Nterminus of SF2/ASF permits RS-domain-independent pre-mRNA splicing. PLoS ONE 2007;2:e854.
35. Cho S, Hoang A, Sinha R, Zhong XY, Fu XD, Krainer AR, et al. Interaction between the RNA binding domains of Ser-Arg splicing factor 1 and U1-70K snRNP protein determines early spliceosome assembly. Proc Natl Acad Sci U S A 2011;108:8233-8.
36. Colwill K, Pawson T, Andrews B, Prasad J, Manley JL, Bell JC, et al. The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. EMBO J 1996;15:265-75.
37. Nayler O, Stamm S, Ullrich A. Characterization and comparison of four serine- and arginine-rich (SR) protein kinases. Biochem J 1997;326: 693-700.
38. Gui JF, Lane WS, Fu XD. A serine kinase regulates intracellular localization of splicing factors in the cell cycle. Nature 1994;369: 678-82.
39. Koizumi J, Okamoto Y, Onogi H, Mayeda A, Krainer AR, Hagiwara M. The subcellular localization of SF2/ASF is regulated by direct interaction with SR protein kinases (SRPKs). J Biol Chem 1994;274: 11125-31.
40. Rossi F, Labourier E, Forné T, Divita G, Derancourt J, Riou JF, et al. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 1996;381:80-2.
41. Misteli T, Spector DL. Serine/threonine phosphatase 1 modulates the subnuclear distribution of pre-mRNA splicing factors. Mol Biol Cell 1996;7:1559-72.
42. Novoyatleva T, Heinrich B, Tang Y, Benderska N, Butchbach ME, Lorson CL, et al. Protein phosphatase 1 binds to the RNA recognition motif of several splicing factors and regulates alternative pre-mRNA processing. Hum Mol Genet 2008;17:52-70.
43. Misteli T, Cáceres JF, Clement JQ, Krainer AR, Wilkinson MF, Spector DL. Serine phosphorylation of SR proteins is required for their recruitment to sites of transcription in vivo. J Cell Biol 1998;143:297-307.
44. Aubol BE, Chakrabarti S, Ngo J, Shaffer J, Nolen B, Fu XD, et al. Processive phosphorylation of alternative splicing factor/splicing factor 2. Proc Natl Acad Sci U S A 2003;100:12601-6.
45. Velazquez-Dones A, Hagopian JC, Ma CT, Zhong XY, Zhou H, Ghosh G, et al. Mass spectrometric and kinetic analysis of ASF/SF2 phosphorylation by SRPK1 and Clk/Sty. J Biol Chem 2005;280:41761-8.
46. Xiang S, Gapsy V, Kim HY, Bessonov S, Hsiao HH, Mohlmann S, et al. Phosphorylation drives a dynamic switch in serine/arginine rich proteins. Structure 2013;21:2162-74.
47. Lai MC, Li RI, Huang SY, Tsai CW, Tarn WY. A human importin-beta family protein, transportin-SR2, interacts with the phosphorylated RS domain of SR proteins. J Biol Chem 2000;275:7950-7.
48. Kataoka N, Bachorik JL, Dreyfuss G. Transportin-SR, a nuclear import receptor for SR proteins. J Cell Biol 1999;145:1145-52.
49. Sinha R, Allemand E, Zhang Z, Karni R, Myers MP, Krainer AR. Arginine methylation controls the subcellular localization and functions of the oncoprotein splicing factor SF2/ASF. Mol Cell Biol 2010;30:2762-74.
50. Zhang Z, Krainer AR. Involvement of SRproteins inmRNAsurveillance. Mol Cell 2004;16:597-607.
51. Sato H, Hosoda N, Maquat LE. Efficiency of the pioneer round of translation affects the cellular site of nonsense-mediated mRNA decay. Mol Cell 2008;29:255-62.
52. Huang Y, Gattoni R, Stévenin J, Steitz JA. SR splicing factors serve as adapter proteins for TAP-dependent mRNA export. Mol Cell 2003;11: 837-43.
53. Lai MC, Tarn WY. Hypophosphorylated ASF/SF2 binds TAP and is present in messenger ribonucleoproteins. J Biol Chem 2004;279: 31745-9.
54. Tintaru AM, Hautbergue GM, Hounslow AM, Hung M, Lian L, Craven CJ, et al. Structural and functional analysis of RNA and TAP binding to SF2/ASF. EMBO Rep 2007;8:756-62.
55. Sanford JR, Gray NK, Beckmann K, Cáceres JF. A novel role for shuttling SR proteins in mRNA translation. Genes Dev 2004;18: 755-68.
56. Michlewski G, Sanford JR, Cáceres JF. The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4EBP1. Mol Cell 2008;30:179-89.
57. Karni R, Hippo Y, Lowe SW, Krainer AR. The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proc Natl Acad Sci U S A 2008; 105:15323-27.
58. Ben-Hur V, Denichenko P, Siegfried Z, Maimon A, Krainer AR, Davidson B, et al. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep 2013;3:103-15.
59. Wu H, Sun S, Tu K, Gao Y, Xie B, Krainer AR, et al. A splicingindependent function of SF2/ASF in microRNA processing. Mol Cell 2010;38:67-77.
60. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-31.
61. Loomis RJ, Naoe Y, Parker JB, Savic V, Bozovsky MR, Macfarlan T, et al. Chromatin binding of SRp20 and ASF/SF2 and dissociation from mitotic chromosomes is modulated by histone H3 serine 10 phosphorylation. Mol Cell 2009;33:450-61.
62. Pradeepa MM, Sutherland HG, Ule J, Grimes GR, Bickmore WA. Psip1/ Ledgf p52 binds methylated histone H3K36 and splicing factors and contributes to the regulation of alternative splicing. PLoS Genet 2012;8:e1002717.
63. Pelisch F, Gerez J, Druker J, Schor II, Muñoz MJ, Risso G, et al. The serine/arginine-rich protein SF2/ASF regulates protein sumoylation. Proc Natl Acad Sci U S A 2010;107:16119-24.
64. Fregoso OI, Das S, Akerman M, Krainer AR. Splicing factor oncoprotein SRSF1 stabilizes p53 via RPL5 and induces cellular senescence. Mol Cell 2011;50:56-66.
65. Longman D, Johnstone IL, Cáceres JF. Functional characterization of SR and SR-related genes in Caenorhabditis elegans. EMBO J 2000;19:1625-37.
66. Sun S, Zhang Z, Sinha R, Karni R, Krainer AR. SF2/ASF autoregulation involves multiple layers of post-transcriptional and translational control. Nat Struct Mol Biol 2010;17:306-12.
67. Gout S, Brambilla E, Boudria A, Drissi R, Lantuejoul S, Gazzeri S, et al. Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma. PLoS ONE 2012;7:e46539.
68. Sinclair CS, Rowley M, Naderi A, Couch FJ. The 17q23 amplicon and breast cancer. Breast Cancer Res Treat 2003;78:313-22.
69. Das S, Anczuków O, Akerman M, Krainer AR. Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep 2012;1:110-7.
70. Valacca C, Bonomi S, Buratti E, Pedrotti S, Baralle FE, Sette C, et al. Sam68 regulates EMT through alternative splicing-activated nonsense- mediated mRNA decay of the SF2/ASF proto-oncogene. J Cell Biol 2010;191:87-99.
71. Gautrey HL, Tyson-Capper AJ. Regulation of MCL-1 by SRSF1 and SRSF5 in cancer cells. PLoS ONE 2012;7:e51497.
72. Ezponda T, Pajares MJ, Agoretta J, Echeveste JI, López-Picazo JM, Torre W, et al. The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Clin Cancer Res 2010;16:4113-25.
73. Fu Y, Huang B, Shi Z, Han J, Wang Y, Huangfu J, et al. SRSF1 and SRSF9RNAbinding proteins promote Wnt signalling-mediated tumorigenesis by enhancing b-catenin biosynthesis. EMBO Mol Med 2013;5:737-50.
74. Shimoni-Sebag A, Lebenthal-Loinger I, Zender L, Karni R. RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1- MAPK-ERK activation and cellular transformation. Carcinogenesis 2013;34:2498-504.
75. Cazalla D, Zhu J, Manche L, Huber E, Krainer AR, Cáceres JF. Nuclear export and retention signals in the RS domain of SR proteins. Mol Cell Biol 2002;22:6871-82.
76. Das S, Fregoso OI, Krainer AR. A new path to oncogene-induced senescence: at the crossroads of splicing and translation. Cell Cycle 2013;12:1477-9.
77. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004;64:7647-54.
78. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet 2008;24:7-10
79. Jia R, Li C, McCoy JP, Deng C, Zheng Z. SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance. Int J Biol Sci 2010;6:806-26.
80. Cohen-Eliav M, Golan-Gerstl R, Siegfried Z, Andersen CL, Thorsen K, Orntoft TF, et al. The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers. J Pathol 2013;229: 630-9.
81. Golan-Gerstl R, Cohen M, Shilo A, Suh SS, Bakacs A, Coppola L, et al. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res 2011; 71:4464-72.
82. Lefave CV, Squatrito M, Vorlova S, Rocco GL, Brennan CW, Holland EC, et al. Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J 2011;30:4084-97.
83. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamota R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-9.
84. Je EM, Yoo NJ, Kim YJ, Kim MS, Lee SH. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors. Int J Cancer 2013;133:260-5.
85. Leu S, Lin YM, Wu CH, Ouyang P. Loss of Pnn expression results in mouse early embryonic lethality and cellular apoptosis through SRSF1-mediated alternative expression of Bcl-xS and ICAD. J Cell Sci 2012;125:3164-72.
86. Jiang ZH, Zhang WJ, Rao Y, Wu JY. Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. Proc Natl Acad Sci U S A 1998;95:9155-60.
87. Massiello A, Chalfant CE. SRp30a (ASF/SF2) regulates the alternative splicing of caspase-9 pre-mRNA and is required for ceramide-responsiveness. J Lipid Res 2006;47:892-7.
88. Olshavsky NA, Comstock CE, Schiewer MJ, Augello MA, Hyslop T, Sette C, et al. Identification of ASF/SF2 as a critical, allelespecific effector of the cyclin D1b oncogene. Cancer Res 2010; 70:3975-84.
89. Moulton VR, Tsokos GC. Alternative splicing factor/splicing factor 2 regulates the expression of the zeta subunit of the human T cell receptor-associated CD3 complex. J Biol Chem 2010;285:12490-6.
90. Galiana-Arnoux D, Lejeune F, Gesnel MC, Stévenin J, Breathnach R, Del Gatto-Konczak F. The CD44 alternative v9 exon contains a splicing enhancer responsive to the SR proteins 9G8, ASF/SF2, and SRp20. J Biol Chem 2003;278:32943-53.
91. Blanco FJ, Bernabeu C. Alternative splicing factor or splicing factor-2 plays a key role in intron retention of the endoglin gene during endothelial senescence. Aging Cell 2011;10:896-907.
92. Lopez-Mejia IC, De Toledo M, Seta FD, Fafet P, Rebouissou C, Deleuze V, et al. Tissue-specific and SRSF1-dependent splicing of fibronectin, a matrix protein that controls host cell invasion. Mol Biol Cell 2013;24:3164-76.
93. Kondo S, Yamamoto N, Murakami T, Okumura M, Mayeda A, Imaizumi K. Tra2 beta, SF2/ASF and SRp30c modulate the function of an exonic splicing enhancer in exon 10 of tau pre-mRNA. Genes Cells 2004;9:121-30.
94. Maimon A, Mogilevsky M, Shilo A, Golan-Gerstl R, Obiedat A, Ben-Hur V, et al. Mnk2 alternative splicing modulates the p39-MAPK pathway and impacts Ras-induced transformation. Cell Rep 2014;7:501-13.
95. Thorsen K, Mansilla F, Schepeler T,Øster B, Rasmussen MH, Dyrskjøt L, et al. Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway. Mol Cell Proteomics 2011;10: M110002998.
96. Lee M, Dworkin AM, Gildea D, Trivedi NS, NISC Comparative Sequencing Program, Moorhead GB, et al. RRP1B is a metastasis modifier that regulates the expression of alternative mRNA isoforms through interactions with SRSF1. Oncogene 2014;33:1818-27.
97. Trzcińska-Daneluti AM, Górecki A, Czubaty A, Kowalska-Loth B, Girstun A, Murawska M, et al. RRM proteins interacting with the cap region of topoisomerase I. J Mol Biol 2007;369:1098-112.